Early-phase clinical trials in adults with ALK-driven or ROS1-driven NSCLC demonstrated objective and durable responses to single-agent lorlatinib, including patients with central nervous system (CNS) metastases and those previously treated with other ALK TKIs20. This evidence concerns the gene ALK and non-small cell lung carcinoma.